$PMCB Releases Corporate Video

PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box^(R), today announced that it has launched a new corporate video. In the video viewers will learn the PharmaCyte Biotech story first hand through interviews and footage shot in Singapore, Thailand, Sweden and Arizona.

PharmaCyte Biotech’s Corporate Video can be viewed at www.PharmaCyte.com/media.

The video documents PharmaCyte Biotech’s live-cell encapsulation technology, Cell-in-a-Box^(R), and how it is produced in Singapore and Thailand. Viewers will learn of the technology’s advantages over other encapsulation technologies, improvements that have been made to the technology since the first clinical trials and how PharmaCyte Biotech will use Cell-in-a-Box^(R) in treatments for diabetes, cancer and symptoms related to solid cancerous tumors. PharmaCyte Biotech’s cancer and diabetes portfolios will also be featured, complete with preclinical and clinical data highlighting the technology’s performance.

Kenneth L. Waggoner, Chief Executive Officer of PharmaCyte Biotech, said, “We are excited to present this video. This video will take viewers right into each of the facilities that have been and will be so instrumental in our success in both cancer and diabetes. The rich footage and stellar interviews highlight what we feel is a formidable story in the biotech industry.”

Mr. Waggoner went on to say, “We have so many people to thank for their time and participation in getting this documentary-like video produced. First, we’d like to thank our partner, Austrianova, and Prof. Walter H. Gunzburg, and Dr. Brian Salmons for letting us spend time with them at their facilities in Singapore and Thailand. We are grateful to Dr. Matthias Lohr for taking time out of his extremely busy schedule to host us at the Karolinska Institute in Stockholm, Sweden. Finally, we’d like to extend many thanks to the entire team at Translational Drug Development (TD2) and Dr. Stephen Gately, the Chief Executive Officer of TD2, for letting us spend a couple of days at TD2’s facility on the Mayo Clinic campus in Scottsdale, Arizona.”

About PharmaCyte Biotech

PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box^(R). This unique and patented technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built. PharmaCyte Biotech’s treatment for pancreatic cancer involves low doses of the well-known anticancer prodrug ifosfamide, together with encapsulated live cells, which convert ifosfamide into its active or “cancer-killing” form. These capsules are placed as close to the cancerous tumor as possible to enable the delivery of the highest levels of the cancer-killing drug at the source of the cancer. This “targeted chemotherapy” has proven remarkably effective in past clinical trials.

PharmaCyte Biotech is also working towards improving the quality of life for patients with advanced pancreatic cancer and on treatments for other types of solid cancerous tumors. In addition, PharmaCyte Biotech is developing treatments for cancer based upon chemical constituents of the Cannabis plant, known as cannabinoids. In doing so, PharmaCyte Biotech is examining ways to exploit the benefits of Cell-in-a-Box^(R) technology in optimizing the anticancer effectiveness of cannabinoids, while minimizing or outright eliminating the debilitating side effects usually associated with cancer treatments. This provides PharmaCyte Biotech the rare opportunity to develop “green” approaches to fighting deadly diseases, such as cancer of the pancreas, brain and breast, which affect hundreds of thousands of individuals worldwide every year.

Safe Harbor

This press release may contain forward-looking statements regarding PharmaCyte Biotech and its future events and results that involve inherent risks and uncertainties. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan” and similar expressions, as they relate to PharmaCyte Biotech or its management, are intended to identify forward-looking statements. Important factors, many of which are beyond the control of PharmaCyte Biotech, could cause actual results to differ materially from those set forth in the forward-looking statements. They include PharmaCyte’s ability to continue as a going concern, delays or unsuccessful results in preclinical and clinical trials, flaws or defects regarding its product candidates, changes in relevant legislation or regulatory requirements, uncertainty of protection of PharmaCyte Biotech’s intellectual property and PharmaCyte Biotech’s continued ability to raise capital. PharmaCyte Biotech does not assume any obligation to update any of these forward-looking statements.

More information about PharmaCyte Biotech can be found at www.PharmaCyte.com. It can also be obtained by contacting Investor Relations.

Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856
Email: InvestorRelations@PharmaCyte.com